{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:29:29Z","timestamp":1785288569369,"version":"3.55.0"},"reference-count":163,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic hepatitis B virus (HBV) infection has been implicated in the development of liver diseases, such as hepatitis, fibrosis, cirrhosis, and cancer, which negatively affect the patients\u2019 quality of life and impacts a high economic strain on patients. The persistence of covalently closed circular DNA (cccDNA) allows the propagation of the infection, and no drug have been developed to completely eliminate cccDNA. The available drugs for chronic hepatitis B (CHB) are classified into nucleos(t)ide analogs (NAs) and interferon-\u03b1 (IFN-\u03b1)\/pegylated interferon \u03b1 (Peg-IFN-\u03b1). However, these treatments do not effectively eradicate hepatitis B surface antigen (HBsAg) and their clinical efficacy is limited. The potential of IFN-based clinical cure is increasingly attracting interest from hepatologists, but the therapeutic outcomes of this intervention are suboptimal and some of them are associated with various complications. Although several novel antiviral drugs are being investigated, however, achieving a clinical cure based on monotherapy is currently challenging. The efficacy of IFN therapy is influenced by host and viral factors. This article provides a comprehensive review of host-related factors that affect the IFN therapy for CHB. A thorough understanding and management of these host-related factors will enhance the efficacy of interferon treatment, minimize adverse reactions, improve patient tolerance, and thereby increasing the clinical cure rate of hepatitis B.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1603544","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T04:10:31Z","timestamp":1750997431000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Virus-host interaction mechanisms in interferon therapy for hepatitis B virus infection: recent advances"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiebing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minmin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengkang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00307-4","article-title":"WHO\u2019s 2024 global hepatitis report","volume":"24","author":"Burki","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20240415-00206","article-title":"Research progress on clinical antiviral treatment of chronic hepatitis B in children","volume":"32","year":"2024","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323979","article-title":"Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis","volume":"71","author":"Hall","year":"2022","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27323","article-title":"Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections","volume":"61","author":"Rehermann","year":"2015","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3760\/cma.j.issn.1007-3418.2019.08.003","article-title":"The expert consensus on clinical cure (functional cure) of chronic hepatitis B","volume":"27","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733364","article-title":"Interferon and hepatitis B: current and future perspectives","volume":"12","author":"Ye","year":"2021","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00560-17","article-title":"Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus","volume":"61","author":"Berke","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051349","article-title":"Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives","volume":"11","author":"Taverniti","year":"2022","journal-title":"J Clin Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20221204-00607","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"30","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1811064116","article-title":"Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization","volume":"116","author":"Iwamoto","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antiviral Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jhep.2024.06.032","article-title":"Neuropilin-1 is a novel host factor modulating the entry of hepatitis B virus","volume":"82","author":"Yu","year":"2025","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e13205","DOI":"10.1111\/cmi.13205","article-title":"Hepatitis B virus entry into HepG2-NTCP cells requires clathrin-mediated endocytosis","volume":"22","author":"Herrscher","year":"2020","journal-title":"Cell Microbiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.02.007","article-title":"Virus entry: open sesame","volume":"124","author":"Marsh","year":"2006","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02303-05","article-title":"Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events","volume":"80","author":"Rabe","year":"2006","journal-title":"J Virol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","author":"Seeger","year":"2015","journal-title":"Virology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","author":"Levrero","year":"2009","journal-title":"J Hepatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(99)70289-1","article-title":"Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection","volume":"117","author":"Maini","year":"1999","journal-title":"Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00219","article-title":"Hepatitis B virus-specific CD8+ T cells maintain functional exhaustion after antigen reexposure in an acute activation immune environment","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1053\/j.gastro.2009.05.047","article-title":"Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections","volume":"137","author":"Oliviero","year":"2009","journal-title":"Gastroenterology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.12.1755","article-title":"Blocking chemokine responsive to gamma-2\/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes","volume":"194","author":"Kakimi","year":"2001","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2023.101360","article-title":"Hepatitis-B virus: replication cycle, targets, and antiviral approaches","volume":"63","author":"Nasser","year":"2023","journal-title":"Curr Opin Virol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","article-title":"Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)","volume":"119","author":"De Clercq","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/molecules15095878","article-title":"Discovery and development of anti-HBV agents and their resistance","volume":"15","author":"Kim","year":"2010","journal-title":"Molecules"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1600-065X.2008.00698.x","article-title":"Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha\/beta, IFN-gamma, and IFN-lambda in host defense","volume":"226","author":"Zhang","year":"2008","journal-title":"Immunol Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2006.00716.x","article-title":"Interferon signalling network in innate defence","volume":"8","author":"Takaoka","year":"2006","journal-title":"Cell Microbiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01707","article-title":"Interferon lambda genetics and biology in regulation of viral control","volume":"8","author":"Hemann","year":"2017","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-051116-052331","article-title":"Intracellular nucleic acid detection in autoimmunity","volume":"35","author":"Crowl","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s0169-409x(02)00027-3","article-title":"Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications","volume":"54","author":"Wang","year":"2002","journal-title":"Adv Drug Delivery Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coviro.2016.01.001","article-title":"Type I interferons in viral control and immune regulation","volume":"16","author":"Teijaro","year":"2016","journal-title":"Curr Opin Virol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2017.03.008","article-title":"Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review","volume":"83","author":"Chen","year":"2017","journal-title":"J Autoimmun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1114","article-title":"Direct effects of type I interferons on cells of the immune system","volume":"17","author":"Hervas-Stubbs","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab216","article-title":"Pegylated interferon-\u0251 (IFN-\u0251) enhances the inhibitory effect of natural killer cells on regulatory T cells via IFN-\u03b3 in chronic hepatitis B","volume":"224","author":"Yuan","year":"2021","journal-title":"J Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.1038\/s41467-023-43078-5","article-title":"Interferon stimulated immune profile changes in a humanized mouse model of HBV infection","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2178143","article-title":"The characteristics of natural killer cells in chronic hepatitis B patients who received PEGylated-interferon versus entecavir therapy","volume":"2021","author":"Cao","year":"2021","journal-title":"BioMed Res Int"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332290","article-title":"HBcrAg values may predict virological and immunological responses to pegIFN-\u03b1 in NUC-suppressed HBeAg-negative chronic hepatitis B","volume":"73","author":"Vecchi","year":"2024","journal-title":"Gut"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.591269","article-title":"Immunomodulation induced during interferon-\u03b1 Therapy impairs the anti-HBV immune response through CD24(+)CD38(hi) B cells","volume":"11","author":"Fu","year":"2020","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308943","article-title":"Towards an HBV cure: state-of-the-art and unresolved questions\u2013report of the ANRS workshop on HBV cure","volume":"64","author":"Zeisel","year":"2015","journal-title":"Gut"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-016-9714-9","article-title":"Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense","volume":"10","author":"Kong","year":"2016","journal-title":"Hepatol Int"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(98)70318-x","article-title":"Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial","volume":"114","author":"Sokal","year":"1998","journal-title":"Gastroenterology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30050","article-title":"Efficacy and safety of peginterferon alfa-2a (40KD) in children with chronic hepatitis B: the PEG-B-ACTIVE study","volume":"68","author":"Wirth","year":"2018","journal-title":"Hepatology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10631-9","article-title":"Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B","volume":"18","author":"Zhang","year":"2024","journal-title":"Hepatol Int"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1172\/jci111508","article-title":"Mechanisms of fever induced by recombinant human interferon","volume":"74","author":"Dinarello","year":"1984","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nn1949","article-title":"EP3 prostaglandin receptors in the median preoptic nucleus are critical for fever responses","volume":"10","author":"Lazarus","year":"2007","journal-title":"Nat Neurosci"},{"key":"B55","article-title":"Unique side effects of interferon","volume":"65","author":"Aslam","year":"2015","journal-title":"J Pak Med Assoc"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1223062","article-title":"IFN-\u03b1 induced systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report and literature review","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020117-043952","article-title":"Type I interferons in autoimmune disease","volume":"14","author":"Crow","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/s0301-472x(99)00109-5","article-title":"Signaling pathways activated by interferons","volume":"27","author":"Platanias","year":"1999","journal-title":"Exp Hematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2093","article-title":"Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1","volume":"96","author":"Wang","year":"2000","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M106640200","article-title":"Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis","volume":"277","author":"Verma","year":"2002","journal-title":"J Biol Chem"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2009.11.4\/felotrich","article-title":"Major depression during interferon-alpha treatment: vulnerability and prevention","volume":"11","author":"Lotrich","year":"2009","journal-title":"Dialogues Clin Neurosci"},{"key":"B62","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/ijnp\/pyx083","article-title":"Interferon-alpha reduces human hippocampal neurogenesis and increases apoptosis via activation of distinct STAT1-dependent mechanisms","volume":"21","author":"Borsini","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12974-020-02003-z","article-title":"Microglial responses to peripheral type 1 interferon","volume":"17","author":"Aw","year":"2020","journal-title":"J Neuroinflammation"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.05.026","article-title":"Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression","volume":"62","author":"Felger","year":"2007","journal-title":"Biol Psychiatry"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-8993(96)01371-6","article-title":"Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain","volume":"747","author":"Shuto","year":"1997","journal-title":"Brain Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2014.03.006","article-title":"Interferon-stimulated genes: roles in viral pathogenesis","volume":"6","author":"Schoggins","year":"2014","journal-title":"Curr Opin Virol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1034968","article-title":"Interferon and interferon-stimulated genes in HBV treatment","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/v16050764","article-title":"Intracellular host restriction of hepatitis B virus replication","volume":"16","author":"Sinha","year":"2024","journal-title":"Viruses"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2100831","article-title":"Intrahepatic transcriptomics reveals gene signatures in chronic hepatitis B patients responded to interferon therapy","volume":"11","author":"Li","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13099-021-00421-9","article-title":"Potential capacity of interferon-alpha to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus","volume":"13","author":"Wang","year":"2021","journal-title":"Gut Pathog"},{"key":"B71","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12985-024-02589-3","article-title":"Mechanisms underlying the compromised clinical efficacy of interferon in clearing HBV","volume":"21","author":"Lei","year":"2024","journal-title":"Virol J"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.784172","article-title":"Suppression of interferon-\u03b1 Treatment response by host negative factors in hepatitis B virus infection","volume":"8","author":"Wang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/s0968-0004(00)89025-8","article-title":"PKR: a new name and new roles","volume":"20","author":"Proud","year":"1995","journal-title":"Trends Biochem Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)52994-X","article-title":"The eIF-2 alpha protein kinases, regulators of translation in eukaryotes from yeasts to humans","volume":"268","author":"Samuel","year":"1993","journal-title":"J Biol Chem"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s10059-011-1059-6","article-title":"PKR-dependent mechanisms of interferon-\u03b1 for inhibiting hepatitis B virus replication","volume":"32","author":"Park","year":"2011","journal-title":"Mol Cells"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3851\/imp3239","article-title":"RIG-I enhances interferon-\u03b1 response by promoting antiviral protein expression in patients with chronic hepatitis B","volume":"23","author":"Wu","year":"2018","journal-title":"Antivir Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0854.2002.31003.x","article-title":"Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity","volume":"3","author":"Haller","year":"2002","journal-title":"Traffic"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02031-21","article-title":"Myxovirus resistance protein A as a marker of viral cause of illness in children hospitalized with an acute infection","volume":"10","author":"Piri","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2416811122","article-title":"Antiviral Mx proteins have an ancient origin and widespread distribution among eukaryotes","volume":"122","author":"Langley","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2018.292391","article-title":"Interferon-inducible myxovirus resistance proteins: potential biomarkers for differentiating viral from bacterial infections","volume":"65","author":"Zav\u2019yalov","year":"2019","journal-title":"Clin Chem"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.75.6.2684-2691.2001","article-title":"Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein","volume":"75","author":"Gordien","year":"2001","journal-title":"J Virol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25608","article-title":"MxA inhibits hepatitis B virus replication by interaction with hepatitis B core antigen","volume":"56","author":"Li","year":"2012","journal-title":"Hepatology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.12.009","article-title":"Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication","volume":"72","author":"Wang","year":"2020","journal-title":"J Hepatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/v13071366","article-title":"Human APOBEC3 variations and viral infection","volume":"13","author":"Sadeghpour","year":"2021","journal-title":"Viruses"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21187","article-title":"Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication","volume":"43","author":"Bonvin","year":"2006","journal-title":"Hepatology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1745-7270.2007.00275.x","article-title":"Cell-specific regulation of APOBEC3F by interferons","volume":"39","author":"Ying","year":"2007","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2021.1931640","article-title":"Roles of APOBEC3 in hepatitis B virus (HBV) infection and hepatocarcinogenesis","volume":"12","author":"Zhang","year":"2021","journal-title":"Bioengineered"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1997.8676","article-title":"Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G\u2013>A hypermutation","volume":"235","author":"Gunther","year":"1997","journal-title":"Virology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20580","article-title":"G to A hypermutation of hepatitis B virus","volume":"41","author":"Noguchi","year":"2005","journal-title":"Hepatology"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01087-12","article-title":"Viral-load-dependent effects of liver injury and regeneration on hepatitis B virus replication in mice","volume":"86","author":"Tian","year":"2012","journal-title":"J Virol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1126\/science.1092066","article-title":"Inhibition of hepatitis B virus replication by APOBEC3G","volume":"303","author":"Turelli","year":"2004","journal-title":"Science"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2007.01020.x","article-title":"Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression","volume":"10","author":"Zhang","year":"2008","journal-title":"Cell Microbiol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1084\/jem.20182031","article-title":"Interferon-induced guanylate-binding proteins: Guardians of host defense in health and disease","volume":"216","author":"Tretina","year":"2019","journal-title":"J Exp Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12929-021-00716-8","article-title":"When human guanylate-binding proteins meet viral infections","volume":"28","author":"Zhang","year":"2021","journal-title":"J BioMed Sci"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2023.07.002","article-title":"Guanylate-binding proteins: mechanisms of pattern recognition and antimicrobial functions","volume":"48","author":"Kirkby","year":"2023","journal-title":"Trends Biochem Sci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29818","article-title":"GBP1, an interferon-inducible GTPase, inhibits Hantaan viral entry by restricting clathrin-mediated endocytosis","volume":"96","author":"Brisse","year":"2024","journal-title":"J Med Virol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02718-15","article-title":"Guanylate-binding protein 1, an interferon-induced GTPase, exerts an antiviral activity against classical swine fever virus depending on its GTPase activity","volume":"90","author":"Li","year":"2016","journal-title":"J Virol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01564-20","article-title":"Identification of the interferon-inducible GTPase GBP1 as major restriction factor for the Hepatitis E virus","volume":"95","author":"Glitscher","year":"2021","journal-title":"J Virol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.psj.2024.103800","article-title":"Guanylate-binding protein 1 inhibits inflammatory factors produced by H5N1 virus through Its GTPase activity","volume":"103","author":"Jiang","year":"2024","journal-title":"Poult Sci"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.33073\/pjm-2024-021","article-title":"Guanylate-binding protein 1 (GBP1) enhances IFN-\u03b1 Mediated antiviral activity against hepatitis B virus infection","volume":"73","author":"Li","year":"2024","journal-title":"Pol J Microbiol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/hep.31282","article-title":"Functional comparison of interferon-\u03b1 Subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon-\u03b1 and interferon-\u03b3 Signaling","volume":"73","author":"Chen","year":"2021","journal-title":"Hepatology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tibs.2017.01.002","article-title":"TRIM family proteins: roles in autophagy, immunity, and carcinogenesis","volume":"42","author":"Hatakeyama","year":"2017","journal-title":"Trends Biochem Sci"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001341","article-title":"To TRIM or not to TRIM: the balance of host-virus interactions mediated by the ubiquitin system","volume":"100","author":"Hage","year":"2019","journal-title":"J Gen Virol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737916","article-title":"Type I interferon-dependent and -independent expression of tripartite motif proteins in immune cells","volume":"38","author":"Rajsbaum","year":"2008","journal-title":"Eur J Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.11550","article-title":"The role of TRIM family proteins in autophagy, pyroptosis, and diabetes mellitus","volume":"45","author":"Wan","year":"2021","journal-title":"Cell Biol Int"},{"key":"B106","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12985-023-02119-7","article-title":"Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during peg-IFN-alpha therapy","volume":"20","author":"Luo","year":"2023","journal-title":"Virol J"},{"key":"B107","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41416-022-02115-8","article-title":"Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis","volume":"128","author":"You","year":"2023","journal-title":"Br J Cancer"},{"key":"B108","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/cm9.0000000000002617","article-title":"TRIM25 inhibits HBV replication by promoting HBx degradation and the RIG-I-mediated pgRNA recognition","volume":"136","author":"Song","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00468-24","article-title":"Tripartite motif-containing protein 21 is involved in IFN-\u03b3-induced suppression of hepatitis B virus by regulating hepatocyte nuclear factors","volume":"98","author":"Won","year":"2024","journal-title":"J Virol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02247-23","article-title":"A novel TRIM22 gene polymorphism promotes the response to PegIFN\u03b1 therapy through cytokine-cytokine receptor interaction signaling pathway in chronic hepatitis B","volume":"11","author":"Wang","year":"2023","journal-title":"Microbiol Spectr"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.78301","article-title":"Tyrosine phosphorylation tunes chemical and thermal sensitivity of TRPV2 ion channel","volume":"11","author":"Mo","year":"2022","journal-title":"Elife"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114095","article-title":"Viral infection and spread are inhibited by the polyubiquitination and downregulation of TRPV2 channel by the interferon-stimulated gene TRIM21","volume":"43","author":"Guo","year":"2024","journal-title":"Cell Rep"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17124","article-title":"TRIM26 inhibits hepatitis B virus replication by promoting HBx degradation and TRIM26 genetic polymorphism predicts PegIFN\u03b1 treatment response of HBeAg-positive chronic hepatitis B Patients","volume":"56","author":"Luo","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00580-23","article-title":"Mitochondrial glycerol-3-phosphate dehydrogenase restricts HBV replication via the TRIM28-mediated degradation of HBx","volume":"97","author":"Liu","year":"2023","journal-title":"J Virol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3390\/biom14081038","article-title":"The role of tripartite motif family proteins in chronic liver diseases: molecular mechanisms and therapeutic potential","volume":"14","author":"Cao","year":"2024","journal-title":"Biomolecules"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2004.09.074","article-title":"Crystal structure of human ISG20, an interferon-induced antiviral ribonuclease","volume":"577","author":"Horio","year":"2004","journal-title":"FEBS Lett"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006296","article-title":"Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA","volume":"13","author":"Liu","year":"2017","journal-title":"PloS Pathog"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2893.2011.01471.x","article-title":"Preactivation of the interferon signalling in liver is correlated with nonresponse to interferon alpha therapy in patients chronically infected with hepatitis B virus","volume":"19","author":"Xiao","year":"2012","journal-title":"J Viral Hepat"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14986","article-title":"Antiviral activity of interferon-stimulated gene 20, as a putative repressor binding to hepatitis B virus enhancer II and core promoter","volume":"35","author":"Park","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01557-22","article-title":"IFIT3 is increased in serum from patients with chronic hepatitis B virus (HBV) infection and promotes the anti-HBV effect of interferon alpha via JAK-STAT2 in vitro","volume":"10","author":"Xu","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B121","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1136\/gutjnl-2020-323126","article-title":"RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes","volume":"71","author":"Sun","year":"2022","journal-title":"Gut"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.634937","article-title":"The functional and antiviral activity of interferon alpha-inducible IFI6 against hepatitis B virus replication and gene expression","volume":"12","author":"Sajid","year":"2021","journal-title":"Front Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-021-04143-z","article-title":"Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress","volume":"477","author":"Liu","year":"2022","journal-title":"Mol Cell Biochem"},{"key":"B127","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jhep.2024.10.032","article-title":"Metabolic dysfunction-associated steatohepatitis reduces interferon and macrophage liver gene signatures in patients with chronic hepatitis B","volume":"82","author":"Osmani","year":"2025","journal-title":"J Hepatol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12985-025-02642-9","article-title":"Impact of hepatic steatosis on the efficacy of antiviral treatment for chronic hepatitis B and the establishment of predictive model: a cohort study","volume":"22","author":"Ren","year":"2025","journal-title":"Virol J"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e32730","article-title":"Interferon-\u03b1 could induce liver steatosis to promote HBsAg loss by increasing triglyceride level","volume":"10","author":"Wu","year":"2024","journal-title":"Heliyon"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1091786","article-title":"Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU\/ml treated with pegylated interferon","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1007-3418.2012.04.012","article-title":"Impact of liver steatosis on antiviral effects of pegylated interferon-alpha in patients with chronic hepatitis B","volume":"20","author":"Shi","year":"2012","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2015.10.023","article-title":"Hepatic steatosis as a predictive factor of antiviral effect of pegylated interferon therapy in patients with hepatitis B","volume":"47","author":"Gong","year":"2015","journal-title":"Transplant Proc"},{"key":"B133","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3760\/cma.j.issn.1007-3418.2015.02.005","article-title":"Impact of liver steatosis on the curative effect of pegylated interferon-alpha-2a in patients with chronic hepatitis B","volume":"23","author":"Xu","year":"2015","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.119","article-title":"Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01026-9","article-title":"Emerging roles of bile acids in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma","volume":"20","author":"Xun","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00601-8","article-title":"Taurocholic acid inhibits the response to interferon-\u03b1 therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8(+) T and NK cell function","volume":"18","author":"Xun","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2010.07695.x","article-title":"Bile acids increase hepatitis B virus gene expression and inhibit interferon-alpha activity","volume":"277","author":"Kim","year":"2010","journal-title":"FEBS J"},{"key":"B138","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41422-018-0136-1","article-title":"Virus-induced accumulation of intracellular bile acids activates the TGR5-\u03b2-arrestin-SRC axis to enable innate antiviral immunity","volume":"29","author":"Hu","year":"2019","journal-title":"Cell Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.05.005","article-title":"Suppressing FXR promotes antiviral effects of bile acids via enhancing the interferon transcription","volume":"14","author":"Liang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112011","article-title":"Bile acids target mitofusin 2 to differentially regulate innate immunity in physiological versus cholestatic conditions","volume":"42","author":"Che","year":"2023","journal-title":"Cell Rep"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.01835","article-title":"The human gut microbiome - A potential controller of wellness and disease","volume":"9","author":"Kho","year":"2018","journal-title":"Front Microbiol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01551","article-title":"The commensal microbiota and viral infection: A comprehensive review","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676232","article-title":"Intestinal microbiota-A promising target for antiviral therapy","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2022.01.007","article-title":"Microbiota regulation of viral infections through interferon signaling","volume":"30","author":"Wirusanti","year":"2022","journal-title":"Trends Microbiol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2155018","article-title":"Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response","volume":"15","author":"Shen","year":"2023","journal-title":"Gut Microbes"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1424775112","article-title":"Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota","volume":"112","author":"Chou","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263844","article-title":"Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B","volume":"17","author":"Nagura","year":"2022","journal-title":"PloS One"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2022.0130","article-title":"Peripheral circulating exosomal-miRNAs potentially mediate the sensitivity to interferon treatment in chronic hepatitis B virus patients","volume":"36","author":"Huang","year":"2023","journal-title":"Viral Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15281","article-title":"Hepatic exosomes with declined MiR-27b-3p trigger RIG-I\/TBK1 signal pathway in macrophages","volume":"42","author":"You","year":"2022","journal-title":"Liver Int"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105584","article-title":"miR-548c-3p targets TRIM22 to attenuate the Peg-IFN-\u03b1 therapeutic efficacy in HBeAg-positive patients with chronic hepatitis B","volume":"213","author":"Lin","year":"2023","journal-title":"Antiviral Res"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix140","article-title":"Plasma microRNA levels are associated with hepatitis B e antigen status and treatment response in chronic hepatitis B patients","volume":"215","author":"van der Ree","year":"2017","journal-title":"J Infect Dis"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2019.103919","article-title":"MiR-3613-3p impairs IFN-induced immune response by targeting CMPK1 in chronic hepatitis B","volume":"74","author":"Zhao","year":"2019","journal-title":"Infect Genet Evol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19071940","article-title":"Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients","volume":"19","author":"Fujita","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1488055","article-title":"ZNF350 gene polymorphisms promote the response to Peg-IFN\u03b1 therapy through JAK-STAT signaling pathway in patients with chronic hepatitis B","volume":"15","author":"Guo","year":"2024","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jhep.2023.09.039","article-title":"Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-\u03b1-treated patients with chronic hepatitis B","volume":"80","author":"Guan","year":"2024","journal-title":"J Hepatol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093089","article-title":"Possible relevance of PNPLA3 and TLL1 gene polymorphisms to the efficacy of PEG-IFN therapy for HBV-infected patients","volume":"21","author":"Enomoto","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B159","doi-asserted-by":"publisher","first-page":"79","DOI":"10.7507\/1001-5515.202301014","article-title":"Interferon-related gene array in predicting the efficacy of interferon therapy in chronic hepatitis B","volume":"40","author":"Wang","year":"2023","journal-title":"Sheng Wu Yi Xue Gong Cheng Xue Za Zhi"},{"key":"B160","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12985-022-01753-x","article-title":"Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells","volume":"19","author":"Zhang","year":"2022","journal-title":"Virol J"},{"key":"B161","doi-asserted-by":"publisher","first-page":"7455","DOI":"10.1038\/s41598-021-86836-5","article-title":"Bayesian analysis of cytokines and chemokine identifies immune pathways of HBsAg loss during chronic hepatitis B treatment","volume":"11","author":"Narayanan","year":"2021","journal-title":"Sci Rep"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2277389","article-title":"Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress","volume":"32","author":"Mak","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1603544\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T04:10:36Z","timestamp":1750997436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1603544\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":163,"alternative-id":["10.3389\/fimmu.2025.1603544"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1603544","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"article-number":"1603544"}}